XWXin Wang

Xin Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xin Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Ji-Zhou Zhang

    School of Acupuncture and Tuina, Chengdu University of Traditional Medicine, Chengdu 610075, China

    1 shared publication
  • Jiasi Wu

    Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China; Key Laboratory of Acupuncture for Senile Disease (Chengdu University of TCM), Ministry of Education, Chengdu 611130, China; Acupunctcure Point Effects Key Laboratory of Sichuan Province, Chengdu 611130, China

    1 shared publication
  • Nan-Rui Shi

    School of Acupuncture and Tuina, Chengdu University of Traditional Medicine, Chengdu 610075, China

    1 shared publication
  • Xiu-Ming Hu

    School of Acupuncture and Tuina, Chengdu University of Traditional Medicine, Chengdu 610075, China

    1 shared publication
  • Ya-Fei Zhao

    International Collaborative Center on Big Science Plan for Purine Signalling, Chengdu University of Traditional Chinese Medicine, Chengdu, China; School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

    1 shared publication
  • Yan-Qin Zuo

    School of Acupuncture and Tuina, Chengdu University of Traditional Medicine, Chengdu 610075, China

    1 shared publication

Latest Publications

  • Open Access

    CD73: Friend or Foe in Lung Injury

    by Xiu-Min Hu, Nan-Rui Shi, Ji-Zhou Zhang, Yan-Qin Zuo, Xin Wang, Ya-Fei Zhao, Jia-Si Wu

    Ecto-5′-nucleotidase (CD73) plays a strategic role in calibrating the magnitude and chemical nature of purinergic signals that are delivered to immune cells. Its primary function is to convert extracellular ATP to adenosine in concert with ectonucleoside triphosphate diphosphohydrolase-1 (CD39) in normal tissues to limit an excessive immune response in many pathophysiological events, such as lung injury induced by a variety of contributing factors. Multiple lines of evidence suggest that the location of CD73, in proximity to adenosine receptor subtypes, indirectly determines its positive or negative effect in a variety of organs and tissues and that its action is affected by the transfer of nucleoside to subtype-specific adenosine receptors. Nonetheless, the bidirectional nature of CD73 as an emerging immune checkpoint in the pathogenesis of lung injury is still unknown. In this review, we explore the relationship between CD73 and the onset and progression of lung injury, highlighting the potential value of this molecule as a drug target for the treatment of pulmonary disease.